If the drug doesn't work as a monotherapy, then give up and try to find someone else who wants to take over development. Such was the eminently practical approach taken last week by Amgen Inc. with regard to epratuzumab, also known as LymphoCide, for non-Hodgkin's lymphoma partnered with Immunomedics Inc. in North America and Australia. (BioWorld Financial Watch) Read More
